Comparing the associations between host and tumor factors with survival outcomes with anti‐PD‐1 immunotherapy in metastatic melanoma
Abstract Background Anti‐programmed death‐1 (PD‐1) immunotherapy has drastically improved survival for metastatic melanoma; however, 50% of patients have progression within 6 months despite treatment. In this study, we investigated host, and tumor factors for metastatic melanoma patients treated wit...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2023-02-01
|
| Col·lecció: | Cancer Medicine |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/cam4.5070 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|